Genocea Biosciences (GNCA) Reports Positive 12 Month Efficacy Data From Phase 2 Dose Optimization Trial Evaluating GEN-003 for Genital Herpes
Tweet Send to a Friend
Genocea Biosciences, Inc. (NASDAQ: GNCA) today announced positive 12 month efficacy data from its Phase 2 dose optimization trial evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
